Clinical trial · Interventional
Interferon Alfa in Treating Children With HIV-Related Cancer
A Phase II Study of Alpha Interferon (alphaIFN) In HIV-Related Malignancies - A Pediatric Oncology Group Wide Study
NCT00002621CI-TRIAL-00015200completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating children with an HIV-related cancer including leukemia, non-Hodgkin's lymphoma, CNS lymphoma, or other solid tumors.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Unspecified Childhood Solid Tumor, Protocol Specific | Childhood Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| recombinant interferon alfa | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Alpha interferon (aIFN) treatment
- description
- See detailed description.
- interventionNames
- Biological: recombinant interferon alfa
Primary outcomes (1)
- measure
- Complete response rate for HIV related malignancies treated with interferon
- timeFrame
- Length of study
Secondary outcomes (1)
- measure
- Event Free Survival
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven malignancy diagnosed at any time following confirmation of HIV-positivity, including the following: * Leukemia * Non-Hodgkin's lymphoma * CNS lymphoma * Other solid tumors * Measurable disease * Concurrent registration on protocol POG-9182 required * Confirmed HIV-positive by POG-9182 criteria * Required biology studies completed PATIENT CHARACTERISTICS: Age: * 21 and under Performance status: * Not specified Life expectancy: * More than 4 weeks Hematopoietic: * Absolute neutrophil count at least 1,000/mm\^3 * Platelet count at least 100,000/mm\^3 (unless bone marrow involvement present) Hepatic: * See Disease Characteristics * Bilirubin less than 1.5 times normal * SGPT and SGOT less than 2 times normal (may discuss with Study Coordinator) Renal: * Creatinine less than 1.5 mg/dL Cardiovascular: * Adequate cardiac function by echocardiogram/MUGA scan Other: * Chronically infected patients must be stable enough to meet life expectancy requirement PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior interferon for cancer * Prior interferon alfa for viral infections (i.e., hepatitis) must be discussed with Study Coordinator Chemotherapy: * At least 1 week since prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * At least 1 week since prior radiotherapy Surgery: * Not specified Other: * Prior antiretroviral therapy allowed * At least 1 week since prior acute treatment for any serious or life-threatening infection * No concurrent local treatment unless discussed with the Study Coordinator * No concurrent acute treatment for any serious or life-threatening infection * Concurrent antiretroviral therapy allowed
References
Publications (0)
Data not yet available
No reference posted for this study.